Complement Inhibition for the Treatment of Myasthenia Gravis
Open Access
- 1 December 2020
- journal article
- review article
- Published by Taylor & Francis in ImmunoTargets and Therapy
- Vol. ume 9, 317-331
Abstract
Generalized myasthenia gravis (gMG) is a rare autoimmune disorder affecting the neuromuscular junction (NMJ). Approximately 80– 90% of patients display antibodies directed against the nicotinic acetylcholine receptor (AChR). A major drive of AChR antibody-positive MG pathology is represented by complement activation. The role of the complement cascade has been largely demonstrated in patients and in MG animal models. Complement activation at the NMJ leads to focal lysis of the post-synaptic membrane, disruption of the characteristic folds, and reduction of AChR. Given that the complement system works as an activation cascade, there are many potential targets that can be considered for therapeutic intervention. Preclinical studies have confirmed the efficacy of complement inhibition in ameliorating MG symptoms. Eculizumab, an antibody directed towards C5, has recently been approved for the treatment of AChR antibody-positive gMG. Other complement inhibitors, targeting C5 as well, are currently under phase III study. Complement inhibitors, however, may present prohibitive costs. Therefore, the identification of a subset of patients more or less prone to respond to such therapies would be beneficial. For such purpose, there is a critical need to identify possible biomarkers predictive of therapeutic response, a field not yet sufficiently explored in MG. This review aims to give an overview of the complement cascade involvement in MG, the evolution of complement-inhibiting therapies and possible biomarkers useful to tailor and monitor complement-directed therapies.Keywords
This publication has 83 references indexed in Scilit:
- Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuriaHaematologica, 2013
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic SyndromeNew England Journal of Medicine, 2013
- The complotype: dictating risk for inflammation and infectionTrends in Immunology, 2012
- Extracellular microRNA: A new source of biomarkersMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2011
- Current and emerging therapies for the treatment of myasthenia gravisNeuropsychiatric Disease and Treatment, 2011
- Novel complement inhibitor limits severity of experimentally myasthenia gravisAnnals of Neurology, 2009
- Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: A model agent for long-term complement inhibition in vivoMolecular Immunology, 2008
- Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis ratsClinical and Experimental Immunology, 2006
- Binding of Immune Complexes to Erythrocyte CR1 (CD35): Difference in Requirement of Classical Pathway Components and Indication of Alternative Pathway‐Mediated Binding in C2‐DeficiencyScandinavian Journal of Immunology, 2000
- Myasthenic Antibodies Cross-Link Acetylcholine Receptors to Accelerate DegradationNew England Journal of Medicine, 1978